Jenny Nilsson

Jenny Nilsson

Auto-generated profile, based on publicly available information

Jenny Nilsson

Lund University 1 Division of Clinical Genetics, Department of Laboratory Medicine Lund, Sweden

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2022 in Genes, Chromosomes and Cancer
Verified
Journal Article
Open access
NANatalie Andersson
Natalie Andersson
KSKarim H. Saba
Karim H. Saba
LMLinda Magnusson
Linda Magnusson
JNJenny Nilsson
Jenny Nilsson
JKJenny Karlsson
Jenny Karlsson
DGDavid Gisselsson
David Gisselsson
Chromosomal instability is a common feature in malignant tumors. Previous studies have indicated that inactivation of the classical tumor suppressor genes RB1, CDKN2A, and TP53 may contribute to chromosomal aberrations in cancer by disrupting different aspects of the cell cycle and DNA damage checkpoint machinery. We performed a side-by-side comparison of how inactivation of each of these genes affected chromosomal stability in vitro. Using CRISPR-Cas9 technology, RB1, CDKN2A, and TP53 were independently knocked out in karyotypically normal immortalized cells, after which these cells were followed over time. Bulk RNA sequencing revealed a distinct phenotype with upregulation of pathways related to cell cycle control and proliferation in all three knockouts. Surprisingly, the RB1 and CDKN2A knocked out cell lines did not harbor more copy number aberrations than wild-type cells, despite culturing for months. The TP53-knocked out cells, in contrast, showed a massive amount of copy number alterations and saltatory evolution through whole genome duplication. This side-by-side comparison indicated that the effects on chromosomal stability from inactivation of RB1 and CDKN2A are negligible compared to inactivation of TP53, under the same conditions in a nonstressful environment, even though partly overlapping regulatory pathways are affected. Our data suggest that loss of RB1 and CDKN2A alone is not enough to trigger surviving detectable aneuploid clones while inactivation of TP53 on its own caused massive CIN leading to saltatory clonal evolution in vitro and clonal selection.

13 March 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
JHJakob Hofvander
Jakob Hofvander
JKJan Köster
Jan Köster
SSSaskia Sydow
Saskia Sydow
PPPaul Piccinelli
Paul Piccinelli
FSFredrik Vult von Steyern
Fredrik Vult von Steyern
FMFredrik Mertens
Fredrik Mertens
Purpose: Soft tissue tumors (STT) are highly heterogeneous neoplasms with more than 100 recognized subtypes, many of which lack reliable diagnostic or prognostic markers. We aimed to evaluate the clinical utility of transcriptome sequencing [RNA sequencing (RNA-seq)] in classifying STTs and identifying prognostically relevant subgroups. Experimental Design: We performed RNA-seq on 704 tumors representing 56 histologic subtypes, integrating global gene expression (GGE) profiles, fusion transcript detection, genomic features, and clinicopathologic data. Unsupervised clustering and machine learning approaches were used to refine tumor classification and identify prognostic transcriptomic signatures. Results: We identified more than 200 pathogenic gene fusion transcripts, including 40 not previously described. Strong GGE profiles were seen for many morphologic subtypes, especially for those characterized by specific gene fusions. Sarcomas with complex genomes, such as myxofibrosarcoma, undifferentiated pleomorphic sarcoma, and leiomyosarcoma (LMS), showed less distinct GGE profiles, and for LMS, subclusters correlating with genomic profiles were seen. On the basis of GGE profiles and other data, the diagnosis was changed in 5.7% of the cases. Comparison with follow-up data identified transcriptional subclusters among sarcomas with complex genomes that correlated with metastasis-free survival. Conclusions: Transcriptomic profiling enhances diagnostic precision, uncovers novel oncogenic fusions, and provides prognostic information in STTs. Still, the results of the current study suggest that, due to the morphologic and clinical diversity of these tumors, multicenter collaborative studies are needed to fully explore the potential of RNA-seq in STTs.

1 June 2009 in Atherosclerosis Supplements
Verified
Journal Article
Closed access
Ming ZhaoMing Zhao
Ming Zhao
HBH Björkbacka
H Björkbacka
JNJ Nilsson
J Nilsson
GFG Fredrikson
G Fredrikson

17 June 2026
Verified
Other
Open access
JHJakob Hofvander
Jakob Hofvander
JKJan Köster
Jan Köster
SSSaskia Sydow
Saskia Sydow
PPPaul Piccinelli
Paul Piccinelli
FSFredrik Vult von Steyern
Fredrik Vult von Steyern
FMFredrik Mertens
Fredrik Mertens
Representativeness of Study Participants

17 June 2026
Verified
Other
Open access
PDF file
JHJakob Hofvander
Jakob Hofvander
JKJan Köster
Jan Köster
SSSaskia Sydow
Saskia Sydow
PPPaul Piccinelli
Paul Piccinelli
FSFredrik Vult von Steyern
Fredrik Vult von Steyern
FMFredrik Mertens
Fredrik Mertens
Overlapping fusion genes result in similar expression profiles

17 June 2026
Verified
Other
Open access
JHJakob Hofvander
Jakob Hofvander
JKJan Köster
Jan Köster
SSSaskia Sydow
Saskia Sydow
PPPaul Piccinelli
Paul Piccinelli
FSFredrik Vult von Steyern
Fredrik Vult von Steyern
FMFredrik Mertens
Fredrik Mertens
Batch effects on transcriptomic clustering